Precision Medicine in Oncology®

A group of pharmacologic inhibitors of the enzyme poly ADP ribose polymerase, are gaining ground as a potential strategy for treating triple-negative breast cancer.

Dr. Emily Chan, from Vanderbilt-Ingram Cancer Center, Discusses the VEGF-Trap Agent Aflibercept

Dr. Deirdre Cohen, NYU Medical Oncology Associates, Discusses Hedgehog Pathway Inhibition

A statistical analysis led to the discovery of the first high-risk genetic mutation associated with hereditary prostate cancer.

Mustard derivatives' potent lethality has ensured its descendents a place in oncology treatment regimens today, even amid advances in targeted therapies.

p53 coordinates a number of antiproliferative programs in response to multiple forms of stress, including low oxygen, depletion of ribonucleotides, hyperactivation of growth signaling, and many forms of DNA damage.

As its moniker As its moniker "guardian of the genome" suggests, p53 has become recognized as one of the most important cancer-related molecules in the cell.

The John Theurer Cancer Center (JTCC), at Hackensack University Medical Center in New Jersey, is one of the largest cancer facilities in the US.

Since its discovery, phosphorylation has come to be recognized as a global regulator of cellular activity, and abnormal phosphorylation is implicated in a host of human diseases.

Martin Steffen, MD, PhD, developed phosphorylation signatures that discriminate between lung tumors and normal lung, and is developing signatures for the prediction of therapy response.

Dr. Jose Baselga from Massachusetts General Hospital Describes the Advantages of Dual Blockade

Cancer treatment is moving from a one-size-fits-all approach to personalized medicine, which means matching the right drug with the right tumor characteristics.

Andre Goy, MD, MS, treats lymphoma patients at New Jersey's largest cancer center, Goy, 54, is also a translational researcher widely known for his work showing the first-ever evidence of activity of bortezomib.

Although the use of tumor markers to evaluate patients with breast cancer is well established, the nuances involved in such testing are growing along with the emergence of novel assays and fresh research findings.

Established in 1973 as the University of Pennsylvania's Cancer Center and subsequently renamed in 2002, the Abramson Cancer Center is a world leader in research, patient care, and education.

Dr. Ranee Mehra from Fox Chase Cancer Center Discusses DNA Repair Enzymes

A look at tweaking the corruptive influence of the virus information code to selectively corrupt cancer cells while sparing (normal) cells that do not have a specific cancer phenotype.

Ezra E. W. Cohen, MD, has focused on the role of EGFR inhibitors in much of his research into head and neck cancers.

Dr. Maurie Markman from Cancer Treatment Centers of America Discusses Diagnostic Molecular Testing

Analysts are optimistic about Exact Sciences financial losses because they reflect the heavy investment in clinical trials for a new noninvasive colorectal cancer test.

Dr. Ezra Cohen from the University of Chicago Discusses Head and Neck Cancer Pathways

The Cleveland Clinic has long been at the forefront of cutting-edge medicine and research. The center's reputation as a world leader in a multitude of fields, including oncology, is undisputed.

This year marks more than 20 years of research into the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway.

If IKK kinase, a group of inhibitory proteins, activity is not regulated properly, tumors in the body have the ability to migrate and proliferate.

The scientific strategy of attacking cancer by thwarting angiogenesis has been on a roller coaster ride for the past 40 years